<?xml version="1.0" encoding="UTF-8"?>
<p>First reported in 1976, Ebola virus (EBOV) infections in humans result in case fatality rates of up to 90%, with no approved medical countermeasures (
 <xref rid="B1" ref-type="bibr">1</xref>). Humans infected with EBOV initially present nonspecific, flu-like symptoms, including a sudden onset of fever, headaches, muscle and joint pain, and general fatigue and malaise (
 <xref rid="B2" ref-type="bibr">2</xref>), before progressing to gastrointestinal, respiratory, vascular, and neurological disease (
 <xref rid="B1" ref-type="bibr">1</xref>). A maculopapular rash accompanied by hemorrhagic symptoms may be observed in a proportion of patients (
 <xref rid="B1" ref-type="bibr">1</xref>). Terminal EBOV disease (EVD) is characterized by severe metabolic imbalances, anuria, convulsions, and hypovolemic shock, with death typically due to multiorgan failure and capillary extravasation from vascular permeability and diffuse coagulopathy (
 <xref rid="B2" ref-type="bibr">2</xref>). Recovery in survivors is slow, and neurological symptoms have been reported (
 <xref rid="B3" ref-type="bibr">3</xref>).
</p>
